FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022371214> ?p ?o ?g. }

• W2022371214 endingPage "3130" @default.
• W2022371214 startingPage "3120" @default.
• W2022371214 abstract "Background. Improved survival of children with acute lymphoblastic leukemia (ALL) has made it more difficult to develop new protocols to further improve results. The authors report the pilot experience with the Memorial Sloan-Kettering-New York-II (MSK-NY-II) protocol, based on the New York regimen with changes made in an attempt to improve efficacy while reducing toxicity. Methods. Forty-four of 46 consecutive patients were randomized to one of four regimens varying only in the sequence and mode of administration of the drugs during the first 48 hours of therapy, while the kinetics of the disappearance of the leukemic cells from the bone marrow was monitored with bone marrow aspirates and biopsies on days 0, 2, 7, and 14. Results. Thirty-two high-risk and 12 average-risk patients were randomized. The marrow contained less than 25% blasts in 74.4% and 92.9% by day 7 and 14, respectively. Ninety-three percent achieved remission. Regimens beginning with daunorubicin achieved a greater and more rapid reduction in leukemic cells than those starting with cyclophosphamide. Daunorubicin infusion produced a more rapid cytoreduction than daunorubicin bolus. Two of 41 patients who achieved remission relapsed, and there was one death in remission. With a median follow-up of 54+ months, the event-free survival (EFS) rate was 86% ± 10%. Disease-free survival (DFS) rate at 48 months was 93%. The estimated 4-year EFS rate for the high-risk and average-risk patients were 83 ± 14% and 93 ± 10%, respectively. Four of 18 patients given daunorubicin bolus and 0 of 18 patients given daunorubicin infusion who were monitored with serial echocardiograms had significant decrease in cardiac function (P = 0.10). The major toxicity of the therapy was infections, with 35% of patients developing serious infections during induction and consolidation. Half the patients had an episode of bacteremia from the venous catheter during the 2 years of maintenance. Conclusions. Close monitoring of kinetics of cytoreduction can rapidly distinguish between similar therapies, and the surrogate end-point may reduce the need for the long follow-up periods that may still be required to demonstrate differences in EFS. Continuous infusion of daunorubicin had less cardiotoxicity with faster antileukemic activity than bolus infusion. The MSK-NY-II protocol with an 86% 4-year EFS rate and a 95% DFS rate was a promising new regimen for the treatment of average-risk and high-risk ALL." @default.
• W2022371214 created "2016-06-24" @default.
• W2022371214 creator A5010913859 @default.
• W2022371214 creator A5022647145 @default.
• W2022371214 creator A5031035765 @default.
• W2022371214 creator A5065709368 @default.
• W2022371214 creator A5074352023 @default.
• W2022371214 creator A5085210489 @default.
• W2022371214 date "1993-11-15" @default.
• W2022371214 modified "2023-10-14" @default.
• W2022371214 title "Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan-Kettering-New York-II protocol" @default.
• W2022371214 cites W1903488342 @default.
• W2022371214 cites W1918033056 @default.
• W2022371214 cites W1949967960 @default.
• W2022371214 cites W1972256295 @default.
• W2022371214 cites W1982230933 @default.
• W2022371214 cites W1991413561 @default.
• W2022371214 cites W1999672808 @default.
• W2022371214 cites W2008197447 @default.
• W2022371214 cites W2009117490 @default.
• W2022371214 cites W2026769064 @default.
• W2022371214 cites W2035614318 @default.
• W2022371214 cites W2052041420 @default.
• W2022371214 cites W206881734 @default.
• W2022371214 cites W2068905647 @default.
• W2022371214 cites W2072502760 @default.
• W2022371214 cites W2073912429 @default.
• W2022371214 cites W2085642107 @default.
• W2022371214 cites W2105886206 @default.
• W2022371214 cites W2109348688 @default.
• W2022371214 cites W2145593916 @default.
• W2022371214 cites W2156753735 @default.
• W2022371214 cites W2168866246 @default.
• W2022371214 cites W2223934217 @default.
• W2022371214 cites W2226233012 @default.
• W2022371214 cites W2232468075 @default.
• W2022371214 cites W2247586375 @default.
• W2022371214 cites W2260580799 @default.
• W2022371214 cites W2277110171 @default.
• W2022371214 cites W2336096370 @default.
• W2022371214 cites W2336895600 @default.
• W2022371214 cites W2433324977 @default.
• W2022371214 cites W2461658766 @default.
• W2022371214 cites W4237876736 @default.
• W2022371214 cites W4293241248 @default.
• W2022371214 cites W85883242 @default.
• W2022371214 doi "https://doi.org/10.1002/1097-0142(19931115)72:10<3120::aid-cncr2820721038>3.0.co;2-q" @default.
• W2022371214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8221579" @default.
• W2022371214 hasPublicationYear "1993" @default.
• W2022371214 type Work @default.
• W2022371214 sameAs 2022371214 @default.
• W2022371214 citedByCount "87" @default.
• W2022371214 countsByYear W20223712142012 @default.
• W2022371214 countsByYear W20223712142013 @default.
• W2022371214 countsByYear W20223712142014 @default.
• W2022371214 countsByYear W20223712142015 @default.
• W2022371214 countsByYear W20223712142016 @default.
• W2022371214 countsByYear W20223712142017 @default.
• W2022371214 countsByYear W20223712142018 @default.
• W2022371214 countsByYear W20223712142019 @default.
• W2022371214 countsByYear W20223712142020 @default.
• W2022371214 countsByYear W20223712142023 @default.
• W2022371214 crossrefType "journal-article" @default.
• W2022371214 hasAuthorship W2022371214A5010913859 @default.
• W2022371214 hasAuthorship W2022371214A5022647145 @default.
• W2022371214 hasAuthorship W2022371214A5031035765 @default.
• W2022371214 hasAuthorship W2022371214A5065709368 @default.
• W2022371214 hasAuthorship W2022371214A5074352023 @default.
• W2022371214 hasAuthorship W2022371214A5085210489 @default.
• W2022371214 hasConcept C126322002 @default.
• W2022371214 hasConcept C141071460 @default.
• W2022371214 hasConcept C2776694085 @default.
• W2022371214 hasConcept C2776755627 @default.
• W2022371214 hasConcept C2778461978 @default.
• W2022371214 hasConcept C2780007613 @default.
• W2022371214 hasConcept C2781021840 @default.
• W2022371214 hasConcept C2781413609 @default.
• W2022371214 hasConcept C43376680 @default.
• W2022371214 hasConcept C71924100 @default.
• W2022371214 hasConcept C90924648 @default.
• W2022371214 hasConceptScore W2022371214C126322002 @default.
• W2022371214 hasConceptScore W2022371214C141071460 @default.
• W2022371214 hasConceptScore W2022371214C2776694085 @default.
• W2022371214 hasConceptScore W2022371214C2776755627 @default.
• W2022371214 hasConceptScore W2022371214C2778461978 @default.
• W2022371214 hasConceptScore W2022371214C2780007613 @default.
• W2022371214 hasConceptScore W2022371214C2781021840 @default.
• W2022371214 hasConceptScore W2022371214C2781413609 @default.
• W2022371214 hasConceptScore W2022371214C43376680 @default.
• W2022371214 hasConceptScore W2022371214C71924100 @default.
• W2022371214 hasConceptScore W2022371214C90924648 @default.
• W2022371214 hasIssue "10" @default.
• W2022371214 hasLocation W20223712141 @default.
• W2022371214 hasLocation W20223712142 @default.
• W2022371214 hasOpenAccess W2022371214 @default.
• W2022371214 hasPrimaryLocation W20223712141 @default.
• W2022371214 hasRelatedWork W1575485051 @default.
• W2022371214 hasRelatedWork W1979130534 @default.

• next